Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 6, 2016

Primary Completion Date

January 10, 2017

Study Completion Date

January 10, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

Liothyronine sodium

Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.

DRUG

Placebo

Patient will receive a matching placebo to take twice daily for one week.

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Oregon Health and Science University

OTHER

NCT02760056 - Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study | Biotech Hunter | Biotech Hunter